Differentiated Imaging BioInVision’s CryoViz hi resolution blockface imaging offers sub 10 micron single cell sensitivity in tissue samples, a strong differentiator for preclinical imaging services. This premium capability, coupled with contract research and manufacturing solutions, presents a clear sales target to CROs, university imaging cores, and biotech startups seeking high fidelity tissue data and rapid turnarounds.

Funding Validation Recent NIH SBIR Phase II funding of 2.5M provides independent validation of both technology and commercial potential. Use this momentum when engaging grant funded labs and translational programs, offering funded collaborations, cooperative development opportunities, and service partnerships that align with ongoing SBIR activities.

AI Clinical Edge BioInVision is advancing AI based clinical decision support through IschemiaViz pipeline for cardiovascular diagnostics, expanding the value proposition beyond preclinical imaging. Target cardiology departments, imaging centers, and academic hospitals; propose pilots that connect dynamic CT perfusion data with static CT angiography workflows, enabling a path to clinical deployments and recurring software services.

Pipeline Growth With a lean team, growth will come through partnerships and channel sales. Pursue CROs, contract manufacturers, imaging distributors, and university technology transfer offices to scale market reach, while exploring collaborative development arrangements for new clinical software modules or imaging accessories that complement CryoViz.

Regional Partnerships Regional focus in Cleveland and the broader Midwest creates a regional advantage for building pilot programs and academic collaborations with nearby universities and hospital systems. Develop a regional go to market plan that leverages local funding activity, regional biotech clusters, and co promotional opportunities with nearby research institutions to accelerate awareness and customer acquisition.